CNS Depressants & Muscle Relaxants – Comprehensive Exam Notes

Central Nervous System (CNS) Depressants

• Group of drugs that slow neuronal activity, producing sedation, hypnosis (sleep), muscle relaxation, or anticonvulsant effects.
• Principal contrast with CNS stimulants (see Ch. 13): stimulants ↑ alertness, HR, respiration, BP; depressants ↓ these parameters.
• Major subclasses: benzodiazepines, non-benzodiazepine hypnotics, orexin receptor antagonists, barbiturates, muscle relaxants, selected OTC agents.

Key Terminology

• Sedative – drug that "calms" CNS, reducing nervousness/excitability/irritability without necessarily inducing sleep.
• Hypnotic – drug that produces sleep; usually higher dose of a sedative.
• Sedative-hypnotic – agent whose effect is dose-dependent (low = sedation, high = sleep).
• Sleep – transient, reversible, cyclic loss of consciousness with ↓ motor & sensory activity.
• REM (Rapid Eye Movement) Sleep – dreaming phase; emotional/mental restoration.
• REM Interference – suppression of REM (e.g., barbiturates) → daytime drowsiness, agitation.
• REM Rebound – ↑ REM after drug withdrawal.
• Therapeutic Index – quantitative safety margin: ${\text{TI}=\frac{LD<em>{50}}{ED</em>{50}}}$. Narrow TI = greater toxicity risk (barbiturates).

Physiology of Sleep & Sleep Disorders

• Alternating stages:
– NREM (stages 1-4) – physical restoration.
– REM – mental restoration.
• Normal architecture is cyclic; drugs that disturb REM can impair restorative quality.
• Causes of insomnia: pain, psychiatric disease, environmental noise/light, caffeine, jet lag, shift work, medications, neurologic disorders, obstructive sleep apnea, blindness (↓ melatonin entrainment).

Benzodiazepines

Overview

• Once most-prescribed sedative-hypnotics; currently superseded by newer non-benzos for sleep.
• Favorable efficacy & safety when used correctly; Schedule IV (abuse potential).
• Sub-categories:
– Sedative-hypnotic (e.g., temazepam).
– Anxiolytic (e.g., alprazolam)—anxiety relief.
• Five key sedative-hypnotic agents emphasized: diazepam, midazolam, temazepam, plus others (lorazepam, alprazolam in full lists).

Mechanism of Action

• Bind to benzodiazepine receptor on $\gamma$-aminobutyric acid-A (GABA_A) chloride channel complex → $\uparrow$ GABA inhibitory effect → hyperpolarization → CNS depression.
• Acts in hypothalamus, thalamus, limbic system; minimal REM suppression; negligible induction of microsomal enzymes (≠ barbiturates).

Pharmacologic Effects

• Anxiolysis, sedation, sleep induction, anticonvulsant, muscle relaxation.

Indications

• Insomnia, procedural sedation, balanced anesthesia, seizure control (acute), alcohol withdrawal, skeletal-muscle spasm, agitation.

Contraindications

• Hypersensitivity, pregnancy, narrow-angle glaucoma.

Common Adverse Effects

• Usually mild: headache, dizziness, drowsiness, cognitive impairment, vertigo, lethargy, "hangover" daytime sleepiness, fall risk (elderly).

Toxicity/Overdose

• Triad: somnolence, confusion, diminished reflexes ± coma.
• VS generally stable unless combined w/ other depressants; rarely causes severe respiratory depression alone.
• Management: supportive, airway, fluids; antidote $\rightarrow$ flumazenil (competitive antagonist).

Drug Interactions

• CYP3A4 inhibitors (azole antifungals, verapamil, diltiazem, protease inhibitors, macrolides, grapefruit juice) ↑ benzo levels.
• Additive CNS depression with alcohol, opioids, antihistamines, others.
• Rifampin (CYP inducer) ↓ benzo efficacy.
• Herbal: kava, valerian ↑ sedation.

Representative Agents

• Diazepam (Valium) – first benzo; oral, rectal, IV; uses: anxiety, status epilepticus, muscle spasm, peri-procedural sedation.
• Midazolam (Versed) – short-acting; IV; pre-op & conscious sedation; causes amnesia; HIGH-ALERT.
• Temazepam (Restoril) – intermediate; metabolite of diazepam; PO; sleep induction (take ~1 h pre-bed).

Non-Benzodiazepine Hypnotics

Shared Features
• Chemically distinct from benzos yet bind selectively to benzodiazepine-1 (omega-1) receptor (except ramelteon/tasimelteon).
• Minimal anxiolytic, anticonvulsant, or muscle-relaxant activity.

Orexin Receptor Antagonist

• Suvorexant (Belsomra) – blocks orexin A/B neuropeptides that promote wakefulness.
• $t_{1/2} \approx 12\text{ h}$ → potential daytime somnolence.
• ADRs: drowsiness, headache, dizziness, diarrhea, dry mouth, cough, ↑ cholesterol; more pronounced in women.
• Schedule IV; counsel re driving impairment & complex sleep behaviours.

Barbiturates

General Characteristics

• Introduced 1903; formerly standard hypnotics but largely replaced by safer drugs.
• Habit-forming; Schedule II-IV; VERY narrow TI.

Mechanism

• Potentiate GABA by prolonging Cl⁻ channel opening at GABAA receptor (site: reticular formation/brainstem) → ↓ neuronal excitability. • At high doses may directly activate GABAA channel.
• Induce hepatic microsomal enzymes → ↑ metabolism of many drugs.

Classification by Duration & Uses

• Ultrashort (thiopental, methohexital) – anesthesia induction, short procedures, ↓ ICP.
• Short (pentobarbital) – pre-op sedation, emergency seizure control.
• Intermediate (butabarbital) – sedation/convulsion control.
• Long (phenobarbital) – seizure prophylaxis, neonatal hyperbilirubinemia.

Contraindications

• Pregnancy, severe respiratory disease, significant hepatic/renal impairment, elderly caution.

Adverse Effects

• CVS: vasodilation, hypotension.
• CNS: drowsiness, lethargy, vertigo, paradoxical restlessness (kids).
• Resp: depression, cough.
• Others: agranulocytosis, thrombocytopenia, Stevens-Johnson syndrome.

Toxicity

• "Barb coma" – respiratory depression → arrest; CNS depression from sleep → coma → death.
• Therapeutic coma sometimes induced for refractory seizures (phenobarbital coma).
• Management: airway, O₂, ventilation, pressors, fluids, & urine alkalinization ($\uparrow$ pH → ↑ renal elimination of phenobarbital).

Drug Interactions

• Additive CNS depression with alcohol, benzos, opioids, antihistamines.
• MAOIs prolong effects (↓ metabolism).
• Enzyme induction lowers efficacy of anticoagulants, oral contraceptives, corticosteroids.

Notable Agents

• Pentobarbital (Nembutal) – long-acting; historical sedative, now for pre-op anxiety & status epilepticus.
• Phenobarbital – prototype; long-acting; 1st-line for neonatal seizures, febrile convulsions.

Over-the-Counter (OTC) Hypnotics

• Usually antihistamine-based: doxylamine (Unisom), diphenhydramine (Sominex); combos w/ acetaminophen (Tylenol PM); melatonin.
• Additive respiratory depression with alcohol/other depressants.

Muscle Relaxants

Pharmacology

• Primarily centrally acting (brainstem/spinal cord) → generalized ↓ muscle tone.
• Structural/functional similar to GABA.
• Direct-acting: dantrolene acts on skeletal muscle by inhibiting $Ca^{2+}$ release from sarcoplasmic reticulum.

Indications

• Acute painful musculoskeletal spasm (trauma, strain).
• Chronic spasticity (multiple sclerosis, cerebral palsy, spinal cord injury).
• Malignant hyperthermia (IV dantrolene).
• Best when combined with physical therapy & rest.

Common Adverse Effects

• CNS depression spectrum: euphoria, light-headedness, dizziness, drowsiness, fatigue, muscle weakness.
• Caution with alcohol, benzos, opioids (additive effects).

Overdose

• Mainly CNS depression; treat supportively (airway, ECG, fluids, crystalluria prevention). No specific antidote.

Key Agents

• Baclofen (Lioresal) – PO & intrathecal pump; chronic spasticity; trial dose before implant.
• Cyclobenzaprine (Flexeril, Amrix ER) – most common; causes marked sedation.
• Dantrolene (Dantrium) – direct acting; malignant hyperthermia emergency kit.
• Others: metaxalone, tizanidine, carisoprodol, chlorzoxazone, methocarbamol.

Nursing Process & Care

Assessment

• History: allergies, concurrent meds (Rx, OTC, herbals), substance use, baseline vitals, I&O, supine & erect BP, hepatic/renal function, sleep patterns, muscle tone, pain scale.
• Identify contraindications (pregnancy, glaucoma, severe COPD, hepatic insufficiency).

Implementation

• Administer hypnotics 30-60 min before bedtime (per onset).
• Benzos: monitor for REM rebound, fall risk (elderly).
• Keep side rails up, call light within reach, assist ambulation; avoid smoking in bed.
• Teach avoidance of alcohol & other CNS depressants; consult before OTC use.
• Warn about next-day drowsiness; advise against driving/operating machinery.
• Rebound insomnia possible after 3-4 wk use & abrupt stop.

Evaluation (Therapeutic Outcomes)

• Sleep: longer total sleep, fewer awakenings, ↓ sleep-onset latency, minimal hangover, improved well-being.
• Muscle relaxants: ↓ spasticity/rigidity, ↑ mobility, ↓ pain.

NCLEX-Style Quick Review Questions (Lecture Examples)

1. Benzodiazepines MAY cause next-day drowsiness; NOT safe to combine with alcohol; may disrupt normal sleep cycle slightly.

2. Barbiturates have LOW therapeutic index ⇒ narrow safe-effective dose range; toxicity range narrow & habit-forming.

3. Older adults generally require ~½ usual barbiturate dose (↓ metabolism, ↑ sensitivity).

4. Accurate statement: Baclofen is available in injectable form for implantable pump.

Ethical / Practical Considerations

• Abuse & dependence potential (barbiturates > benzos > z-drugs).
• Polypharmacy in elderly ↑ fall & cognitive-impairment risk; advocate non-pharmacologic sleep hygiene first (light control, routine, CBT-I).
• Monitor for complex sleep behaviors (sleep-driving, cooking) with zolpidem, suvorexant.
• Pregnancy Category D/X for many barbiturates & some benzos ⇒ teratogenicity.

Key Equations / Numerical References

• Therapeutic Index: ${TI=LD<em>{50}/ED</em>{50}}$ (barbiturates TI ≈ 3–10 vs. benzos TI > 100).
• Suvorexant half-life $t_{1/2} = 12\ \text{h}$.
• Temazepam onset $\approx 20\text{–}40\ \text{min}$; counsel to take $\sim 60\ \text{min}$ pre-bedtime.
• Eszopiclone designed for full $8\ \text{h}$ sleep; avoid if need to awaken < 6 h.

High-Yield Summary

• Sedative ≠ hypnotic; dose determines effect.
• Benzos: enhance GABA, ceiling effect on resp ↓, antidote = flumazenil.
• Barbiturates: GABA potentiation + enzyme induction, narrow TI, resp depression major fatal risk.
• Non-benzo "Z-drugs" target sleep with fewer residual effects.
• Orexin antagonist (suvorexant) addresses wakefulness pathway.
• Muscle relaxants primarily central; dantrolene acts peripherally; monitor CNS depression.
• Safety, fall precautions, and patient education are paramount in nursing care.